Erasca, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 97.58. In total, the insiders bought 51 987 014 and sold 10 479 233 ERAS shares in the last 100 trades.

Insider Power

(Last 100 transactions)
97.58
Buy 51 987 014 Shares
Sell 10 479 233 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 20, 2024 Stock Option (right to buy) Buy Varney Michael David 60 000
Jun 20, 2024 Stock Option (right to buy) Buy Start Valerie Denise Harding 60 000
Jun 20, 2024 Stock Option (right to buy) Buy Liu Jean I 60 000
Jun 20, 2024 Stock Option (right to buy) Buy Garner Ebun 160 082
Jun 20, 2024 Stock Option (right to buy) Buy Morris Shannon 137 142
Jun 20, 2024 Stock Option (right to buy) Buy Lim Jonathan E 632 759
Jun 20, 2024 Stock Option (right to buy) Buy Chacko David M. 278 812
Jun 20, 2024 Stock Option (right to buy) Buy Hambleton Julie 60 000
Jun 20, 2024 Stock Option (right to buy) Buy Casdin Alexander W. 60 000
Jun 20, 2024 Stock Option (right to buy) Buy Bristol James Arthur 60 000
Jun 20, 2024 Stock Option (right to buy) Buy Multani Pratik S 60 000
May 21, 2024 Common Stock Buy Casdin Alexander W. 80 000
Feb 05, 2024 Stock Option (right to buy) Buy Lim Jonathan E 1 500 000
Feb 05, 2024 Stock Option (right to buy) Buy Chacko David M. 600 000
Feb 05, 2024 Stock Option (right to buy) Buy Garner Ebun 480 000
Feb 05, 2024 Stock Option (right to buy) Buy Morris Shannon 535 800
Jan 01, 2024 Stock Option (right to buy) Buy Bristol James Arthur 62 747
Jan 01, 2024 Stock Option (right to buy) Buy Multani Pratik S 32 867
Jan 01, 2024 Stock Option (right to buy) Buy Liu Jean I 35 482
Jan 01, 2024 Stock Option (right to buy) Buy Start Valerie Denise Harding 39 590
Jan 01, 2024 Stock Option (right to buy) Buy Casdin Alexander W. 41 084
Dec 15, 2023 Common Stock Buy Chacko David M. 7 478
Dec 15, 2023 Common Stock Buy Garner Ebun 5 448
Dec 06, 2023 Common Stock Buy Start Valerie Denise Harding 10 000
Dec 06, 2023 Common Stock Buy Lim Jonathan E 278 150
Click to get the best stock tips daily for free!

About Erasca, Inc.

Erasca. Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also ... ERAS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT